Lublin Oncology Center pioneers CAR-T therapy for blood cancers, offering hope for patients unresponsive to traditional treatments.
The Hematology and Stem Cell Transplantation Department at the Oncology Center in Lublin is set to launch a groundbreaking therapy for blood cancers. This facility is the first non-academic center in Poland and the only one east of the Vistula River to offer CAR-T treatment, a revolutionary approach for patients who have not responded to conventional therapies.
CAR-T: A Promising Therapy for Resistant Blood Cancers
CAR-T therapy involves modifying a patient’s immune cells to target and destroy cancer cells. This innovative treatment offers hope for patients with advanced blood cancers, achieving long-term remission in up to 50% of cases. Funded entirely by the Polish National Health Fund (NFZ), CAR-T’s high cost—1.8 million PLN per patient—reflects the complexity of producing these “living drugs.”
Lublin Becomes a Leader in CAR-T Therapy
The center has already treated 14 patients with multiple myeloma in clinical trials and will now expand its services, making CAR-T therapy more accessible in eastern Poland. Two young lymphoma patients have been selected for treatment.